Opportunistic Infections in MS What Is the Risk?

Slides:

Advertisements

Similar presentations

AM Report May 4, 2009 Amy Auerbach  Severe demyelinating disease of the central nervous system caused by reactivation of the polyomavirus JC  Occurs.

Advertisements

© 2014 Direct One Communications, Inc. All rights reserved. 1 Infectious Complications of Multiple Sclerosis Therapies Carrie M. Hersh, DO Mellen Center.

FREEDOMS II TRIAL.

Fingolimod Therapy for Multiple Sclerosis

An Analysis of Monthly Surveillance 3T MRI in MS patients switched from long term natalizumab to teriflunomide in a controlled, prospective study K. Edwards,

1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.

Guidelines for Using the Learning Package. Objectives Describe the purpose and overarching structure of the learning package Describe the purpose of each.

Title Authors Introduction Text, text, text, text, text, text Background Information Text, text, text, text, text, text Observations Text, text, text,

Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.

Depression As a Predictor of Mortality and Hospitalization Among Hemodialysis Patients in the United States and Europe.

Carrie M. Hersh, D.O., Robert Fox, M.D.

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

ART and toxicities: CNS

Silent No More:.

Highlights From the 2017 Annual European MS Meeting

Making Decisions With Your Osteoarthritis Patients

MS Highlights From the 2017 Annual Neurology Meeting

Program Goals Teriflunomide: Pooled Safety Data.

A Paradigm Shift in PAH.

Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.

افسردگی شناخت، ارزیابی، و پیشگیری در جمعیت دانشجویی

Immune Reconstitution in MS:

Current Controversies in Multiple Sclerosis Management

افسردگی شناخت، ارزیابی، و پیشگیری در جمعیت دانشجویی

Applying Real-World Evidence in MS: Reviewing the State of the Art

Perspectives on Key MS Data From the Annual Neurology Meeting

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Strategies for Assessing and Preserving Function in ALS

T-Cell Directed Therapy in MS

Assessing Disease Progression in MS Treatment

Updates in Neuronal Ceroid Lipofuscinosis

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Novel Therapies for the Treatment of MS

Are We Closer to Personalized Medicine in MS?

Management Challenges in CLL

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

What Is the Role of Injectables in the Modern Era of MS Treatment?

بسم الله الرحمن الرحیم.

A Case-based Approach to RSV Disease

Program Goals Disclaimer Overview Assessing Disease Activity.

Charting Progress in MS Treatment:

Nat. Rev. Neurol. doi: /nrneurol

Treating to Target in MS

Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Identifying High-Risk AF Patients

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

SLE and Cardiovascular Risk

After the Baby Comes.

Clinical Pearls on Hot Topics in MS

Managing Age-Related Clinical Issues in Hemophilia

Updates in Neuronal Ceroid Lipofuscinosis

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Epidemiology of opportunistic infections in AIDS patients

Calliope A. Dendrou, Lars Fugger Neuron

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Figure 2 JCV index JCV index (A) Fifty samples of natalizumab-treated patients with multiple sclerosis were assessed twice for their anti-JCV antibody.

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Oral Therapies in MS.

Novel Therapeutics in MS

Treatment of Multiple Sclerosis: Old & New

Mitigating Infection Risk With DMT in MS

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

MS, Age, and Immune Function

Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE) Kyle Smoot, MD, FAAN1, Kiren Kresa-Reahl, MD1, Pavle.

Rethinking Risk Stratification for Nonischemic HF:

Understanding the Role of Disability in MS Management

Presentation transcript:

Opportunistic Infections in MS What Is the Risk?

Introduction and Background

Presumed Mechanisms of Opportunistic Infections in MS

PML Natalizumab

PML DMF and Fingolimod

Cryptococcal Infection

Herpesvirus Infection in MS

VZV Infection

Listeriosis

Minimizing Infection Risk Non-PML

Risk Stratification for PML

Clinical Symptoms of PML

Minimizing PML Risk Monitoring MRI

Minimizing PML Risk Monitoring Lymphocyte Counts

Managing Opportunistic Infections JCV and PML

Managing Opportunistic Infections Cryptococci and Listeriosis

Conclusion

Abbreviations